Medivir AB (publ)
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Sweden, the Nordic region, rest of Europe, and internationally. The company offers Xerclear for the treatment of labial herpes under the Zoviduo name; and Olysio to treat hepatitis C. It also develops Remetinostat, a histone deacetylase (HDAC) inhibitor that has completed Phas… Read more
Medivir AB (publ) (MVR0) - Total Assets
Latest total assets as of September 2025: €130.90 Million EUR
Based on the latest financial reports, Medivir AB (publ) (MVR0) holds total assets worth €130.90 Million EUR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Medivir AB (publ) - Total Assets Trend (2021–2024)
This chart illustrates how Medivir AB (publ)’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Medivir AB (publ) - Asset Composition Analysis
Current Asset Composition (December 2024)
Medivir AB (publ)'s total assets of €130.90 Million consist of 38.6% current assets and 61.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 6.3% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €96.31 Million | 55.8% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Medivir AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Medivir AB (publ)'s current assets represent 38.6% of total assets in 2024, a decrease from 67.3% in 2021.
- Cash Position: Cash and equivalents constituted 6.3% of total assets in 2024, up from 4.4% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 55.0% of total assets, an increase from 28.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 55.8% of total assets.
Medivir AB (publ) Competitors by Total Assets
Key competitors of Medivir AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Medivir AB (publ) - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Medivir AB (publ) generates 0.02x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Medivir AB (publ) is currently not profitable relative to its asset base.
Medivir AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.46 | 1.84 | 1.84 |
| Quick Ratio | 0.46 | 1.84 | 1.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-31.80 Million | € 44.60 Million | € 44.60 Million |
Medivir AB (publ) - Advanced Valuation Insights
This section examines the relationship between Medivir AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | -40.1% |
| Total Assets | €172.59 Million |
| Market Capitalization | $15.08 Million USD |
Valuation Analysis
Below Book Valuation: The market values Medivir AB (publ)'s assets below their book value (0.09 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Medivir AB (publ)'s assets decreased by 40.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Medivir AB (publ) (2021–2024)
The table below shows the annual total assets of Medivir AB (publ) from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €172.59 Million | -40.05% |
| 2023-12-31 | €287.91 Million | +22.94% |
| 2022-12-31 | €234.20 Million | -30.26% |
| 2021-12-31 | €335.82 Million | -- |